Royal Bank of Canada
EGRX

Royal Bank of Canada’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Royal Bank of Canada’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-17,000
Closed -$908K – 6888
2017
Q4 		$908K Sell
17,000
-4,600
-21% -$256K ﹤0.01% 3307
2017
Q3 		$1.29M Buy
+21,600
New +$1.31M ﹤0.01% 3016

Other funds holding EGRX

XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $171B AUM 85% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
SLG
Stanley-Laman Group Berwyn, Pennsylvania $984M AUM 72.08% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
AIC
Archer Investment Corporation Carmel, Indiana $508M AUM 24.82% 1-Year Est. Return
Credit Agricole
Credit Agricole Montrouge Cedex, France $38.1B AUM
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

Royal Bank of Canada's EGRX Position: Q4 2024 in Review

Royal Bank of Canada sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q4 2024, closing a stake of 36,925 shares — an estimated $138K sold.

Royal Bank of Canada first reported a position in EGRX in Q1 2014 and held it in 43 quarters. The position peaked at $3.81M in Q2 2017. 9 funds tracked by Wall St. Rank hold EGRX as of Q4 2024.

  • Royal Bank of Canada reported no remaining Eagle Pharmaceuticals, Inc. position as of Q4 2024 after selling out during the quarter.
  • Royal Bank of Canada sold 36,925 Eagle Pharmaceuticals, Inc. shares in Q4 2024, an estimated $138K.
  • Royal Bank of Canada first reported a position in Eagle Pharmaceuticals, Inc. in Q1 2014 and held it in 43 quarters.
  • Royal Bank of Canada's Eagle Pharmaceuticals, Inc. position peaked at $3.81M in Q2 2017.
  • 9 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q4 2024.

Based on Royal Bank of Canada's 13F filing for Q4 2024, filed 14 Feb 2025.